✦ LIBER ✦

PCV48 Systematic Review of Cost-Effectiveness Models for Pharmacologic Stroke Prevention in Atrial Fibrillation

✍ Scribed by B. Limone; W.L. Baker; M. Roberts; C.I. Coleman

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

PCV57 Cost-Effectiveness of Rivaroxaban

✍ A.K. Kapur; I. Chatzitheofilou; L.K. Schang 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 57 KB

PCV50 COST-EFFECTIVENESS ANALYSIS COMPAR

✍ Y. Zhao; L. Lim; C.I. Coleman 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 55 KB

Cost–Effectiveness of Rivaroxaban Compar

✍ Soyon Lee; Moise W. Anglade; Dan Pham; Robyn Pisacane; Jeffrey Kluger; Craig I. 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 786 KB

Cost-effectiveness of apixaban vs warfar

✍ Kamel, H.; Easton, J. D.; Johnston, S. C.; Kim, A. S. 📂 Article 📅 2012 🏛 Lippincott Williams and Wilkins 🌐 English ⚖ 578 KB

COST-EFFECTIVENESS OF APIXABAN COMPARED

✍ Soyon Lee; Moise Anglade; Kelly Hagstrom; Joy Meng; Jeffrey Kluger; Craig Colema 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 89 KB

PCV53 A Cost-Effectiveness Analysis Comp

✍ M. Psenkova; S. Mackovicova; D. Tomek; J. Bielik; H. Spitzerova 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 58 KB